About Medicis
Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. Medicis is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic and aesthetic categories. Medicis' products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and aesthetic elegance.
Medicis' products include the brands Dysport®(TM) (abobotulinumtoxinA), RESTYLANE(R) (hyaluronic acid), PERLANE(R) (hyaluronic acid), DYNACIN(R) (minocycline HCl), LOPROX(R) (ciclopirox), PLEXION(R) (sodium sulfacetamide 10% and sulfur 5%), SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets, TRIAZ(R) (benzoyl peroxide), LIDEX(R) (fluocinonide) Cream 0.05%, VANOS(R) (fluocinonide) Cream 0.1%, ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10%, the LIPOSONIX(R)(3) system and the over-the-counter brand ESOTERICA(R). For more information about Medicis, please visit the Company's website at www.Medicis.com. Printed copies of Medicis' complete audited financial statements are available free of charge upon request.
If you've never heard of Dysport® before, get ready for a revolution when it comes to treating glabellar lines (facial wrinkles). Dysport® is FDA-approved and is the first true competitor to Allergan's Botox in the U.S — and we're one of the first clinics to acquire and peform injections with it.
- $75.00 rebate extended for Dysport ($3.05 per unit) through September 30, 2010!
» Download rebate form
About Dysport®
Dysport® is developed by Medecis, and is an injectable that is signicantly less expensive than Allergan's Botox for a product that may last at least a month longer. For example, injections to front frown lines can be as low as $150.
If you have been waiting to treat yourself, now is the time!
- The active substance in Dysport® is a botulinum neurotoxin type A complex, which acts at the level of the neuromuscular junction in the targeted muscle. Dysport® is a neuromuscular blocking toxin which acts to block acetylcholine release at motor nerve ends and reduces muscular spasm.
- Used in patient care in the United Kingdom since 1991, Dysport® has marketing authorizations in 76 countries for therapeutic use and in 27 countries for aesthetic use.
- Dysport® was initially developed and subsequently approved in many markets around the world, outside the U.S., for the treatment of movement disorders such as cervical dystonia (spasmodic torticollis), blepharospasm (involuntary eye closure), hemifacial spasm and various forms of muscle spasticity, including post-stroke arm spasticity, spasticity of the lower limbs (calf) in adults and children with cerebral palsy. It was later developed for the treatment of a wide variety of neuromuscular disorders and aesthetic medicine.
Important Safety Information
The effects of Dysport® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.
- The dosing Units of Dysport® are not the same as and are not interchangeable with those of other botulinum toxin products.
- Recommended dose and frequency of administration should not be exceeded.
- Caution should be exercised when administering Dysport® to patients with surgical alterations to the facial anatomy, marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep dermal scarring or thick sebaceous skin.
- The clinical effects of treatment may be exacerbated in patients with neuromuscular disorders.
- Dysport® is contraindicated in patients with infection at the proposed injection site, an allergy to cow's-milk protein or a known hypersensitivity to any botulinum toxin product or its components.
- Dysport® is not recommended for use in children or pregnant women.
- In clinical studies, the most frequently reported adverse events (> or = 2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis and nausea.
To report SUSPECTED ADVERSE REACTIONS, call 1-877-397-7671 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
| Treatment | Price | September 2010 Monthly Special |
|---|---|---|
| Dysport® | $2.75 per unit (average cost per area = $147.50) + get a $75 rebate with purchase! |
*Offers are not available with any other offer or sale item. Not good on full price or sale services already purchased. Please note: To receive these specials you must mention that you saw the offer online or received an email. Specials are valid September 1-30, 2010 except for the specials specifically offered between September 4-6 and the Laser Hair Removal specials limited to specific days of the week. No exceptions.